ER and Post-ER Quality Control of Integral Membrane Proteins
完整膜蛋白的 ER 和 ER 后质量控制
基本信息
- 批准号:10798491
- 负责人:
- 金额:$ 1.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-06-01 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:26S proteasomeBiochemicalCell secretionCellsCytoplasmCytosolDegradation PathwayDevelopmentDiseaseEndoplasmic ReticulumEukaryotaEventFoundationsGenetic ScreeningGoalsHealthIntegral Membrane ProteinLinkMembraneMembrane ProteinsModelingMolecularMolecular ChaperonesNamesOrganellesPaperPathway interactionsPeptide HydrolasesPlayProcessProtein BiosynthesisPublicationsPublishingQuality ControlResearchResistanceRoleSortingStressTechnologyTranslation ProcessUbiquitinUbiquitinationdisease-causing mutationexperimental studyextracellularhuman diseasein vitro Assaymembermethod developmentmisfolded proteinpolypeptidepostersprogramsprotein aggregationprotein foldingproteotoxicitytool
项目摘要
Approximately one-third of all newly synthesized proteins in eukaryotes enter the endoplasmic
reticulum (ER). Once associated with this compartment, these nascent polypeptides are post-
translationally processed, acquire their native confirmations, oligomerize, and are sorted for
extracellular secretion or delivery to other organelles. However, many disease-causing
mutations compromise protein folding and maturation, which in turn can generate aggregation-
prone species. To off-set the catastrophic effects that accompany the accumulation of protein
aggregates, misfolded protein substrates are: (i) selected by molecular chaperones associated
with the ER, (ii) modified with ubiquitin, (iii) delivered to the cytoplasm via a process known as
retrotranslocation, and (iv) degraded by the 26S proteasome. Brodsky and colleagues named
this pathway ER associated degradation (ERAD), and over the past 21 years many of the
molecular mechanisms underlying this sequence of events were defined in the Brodsky lab. To
date, ~80 human diseases are linked to the ERAD pathway and >1,200 publications have been
authored on various aspects of this pathway. Ongoing efforts are defining the
pathophysiological foundation of several ERAD-related disorders. In parallel, members of the
Brodsky lab have revealed how key components orchestrate each step during ERAD. In the
past 5 years, the lab has published 64 papers, and tools and technologies were developed that
provide an unprecedented view of the mechanisms that lead to the selection, ubiquitination,
retrotranslocation, and degradation of diverse substrates. Nevertheless, recent discoveries
dictate that more challenging research directions are pursued: By necessity, these next efforts
will require additional method development and a pursuit of longer-term goals. Specific
questions that the research program will address include: What biochemical features define an
ERAD substrate? Which factors are sufficient to drive the retrotranslocation of ERAD substrates,
some of which are aggregation-prone? Do ER-associated proteases function in tandem with the
26S proteasome to destroy substrates that are stably integrated into the ER membrane, and
thus might be retrotranslocation resistant? And, how are retrotranslocated membrane proteins—
which can reside in the cytosol after being liberated from the ER—retained in a soluble state?
Answers to these questions, which lie at the core of research in the field, will significantly
advance an understanding of how cellular health is maintained in the face of proteotoxic stress
as well as how ERAD-associated diseases arise and might be rectified.
在真核生物中,大约三分之一的新合成的蛋白质进入内质
网状结构(ER)。一旦与这个隔室联系在一起,这些新生多肽就是后
翻译处理,获得它们的本机确认,寡聚,并被排序
胞外分泌或输送到其他细胞器。然而,许多致病因素
突变损害了蛋白质的折叠和成熟,进而可以产生聚集-
易受感染的物种。以抵消伴随蛋白质积累的灾难性影响
聚集体,错误折叠的蛋白质底物:(I)由相关的分子伴侣选择
利用内质网,(Ii)用泛素修饰,(Iii)通过称为
逆转易位,以及(Iv)被26S蛋白酶体降解。Brodsky和他的同事被命名为
这条内质网相关降解(ERAD)的途径,在过去的21年里,许多
布罗德斯基实验室对这一系列事件背后的分子机制进行了定义。至
到目前为止,大约有80种人类疾病与ERAD途径有关,已经发表了1200篇出版物
关于这条道路的各个方面的作者。正在进行的努力正在定义
几种ERAD相关疾病的病理生理学基础。同时,委员会的成员
Brodsky实验室揭示了关键组件如何在ERAD期间协调每一步。在
在过去的5年里,该实验室发表了的论文,并开发了
提供了一种前所未有的视角来了解导致选择、泛素化、
不同底物的反向移位和降解。然而,最近的发现
决定追求更具挑战性的研究方向:不可避免地,这些下一步的努力
将需要额外的方法开发和追求更长期的目标。特定的
该研究计划将解决的问题包括:哪些生化特征定义了
Erad底物?哪些因素足以驱动ERAD底物的逆转移位,
其中一些是易于聚合的?内质网相关的蛋白水解酶是否与
26S蛋白酶体,破坏稳定整合到内质网膜上的底物,以及
因此可能对易位有抵抗力?以及,逆转膜蛋白是如何-
从内质网中释放出来后,什么可以留在胞浆中--以可溶的状态保留?
这些问题的答案,是该领域研究的核心,将显著地
加深对如何在蛋白质毒性应激下维持细胞健康的理解
以及与ERAD相关的疾病是如何产生和可能纠正的。
项目成果
期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A positive genetic selection for transmembrane domain mutations in HRD1 underscores the importance of Hrd1 complex integrity during ERAD.
- DOI:10.1007/s00294-022-01227-1
- 发表时间:2022-04
- 期刊:
- 影响因子:2.5
- 作者:
- 通讯作者:
Hsp40s play distinct roles during the initial stages of apolipoprotein B biogenesis.
- DOI:10.1091/mbc.e21-09-0436
- 发表时间:2022-02-01
- 期刊:
- 影响因子:3.3
- 作者:Kumari D;Fisher EA;Brodsky JL
- 通讯作者:Brodsky JL
The generation of detergent-insoluble clipped fragments from an ERAD substrate in mammalian cells.
- DOI:10.1038/s41598-023-48769-z
- 发表时间:2023-12-06
- 期刊:
- 影响因子:4.6
- 作者:
- 通讯作者:
A 14-day pulse of PLX5622 modifies α-synucleinopathy in preformed fibril-infused aged mice of both sexes.
- DOI:10.1016/j.nbd.2023.106196
- 发表时间:2023-08
- 期刊:
- 影响因子:6.1
- 作者:Bhatia TN;Jamenis AS;Abbas M;Clark RN;Miner KM;Chandwani MN;Kim RE;Hilinski W;O'Donnell LA;Luk KC;Shi Y;Hu X;Chen J;Brodsky JL;Leak RK
- 通讯作者:Leak RK
Fundamental and translational research in Cystic Fibrosis - why we still need it.
囊性纤维化的基础和转化研究 - 为什么我们仍然需要它。
- DOI:10.1016/j.jcf.2022.12.010
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Farinha,CarlosM;Brodsky,JeffreyL;Pedemonte,Nicoletta
- 通讯作者:Pedemonte,Nicoletta
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFREY L. BRODSKY其他文献
JEFFREY L. BRODSKY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFREY L. BRODSKY', 18)}}的其他基金
The role of FIT2 in VLDL assembly, hepatic triglyceride homeostasis, and lipoprotein atherogenicity
FIT2 在 VLDL 组装、肝甘油三酯稳态和脂蛋白致动脉粥样硬化中的作用
- 批准号:
10638637 - 财政年份:2023
- 资助金额:
$ 1.76万 - 项目类别:
Interinstitutional Program in Cell and Molecular Biology: A Graduate Training Path to Promote Traditional and Non-Traditional Professional Outcomes
细胞和分子生物学机构间项目:促进传统和非传统专业成果的研究生培训路径
- 批准号:
10421289 - 财政年份:2020
- 资助金额:
$ 1.76万 - 项目类别:
Interinstitutional Program in Cell and Molecular Biology: A Graduate Training Path to Promote Traditional and Non-Traditional Professional Outcomes
细胞和分子生物学机构间项目:促进传统和非传统专业成果的研究生培训路径
- 批准号:
10192522 - 财政年份:2020
- 资助金额:
$ 1.76万 - 项目类别:
ER and post-ER quality control of integral membrane proteins
完整膜蛋白的 ER 和 ER 后质量控制
- 批准号:
10626023 - 财政年份:2019
- 资助金额:
$ 1.76万 - 项目类别:
ER and post-ER quality control of integral membrane proteins
完整膜蛋白的 ER 和 ER 后质量控制
- 批准号:
10176534 - 财政年份:2019
- 资助金额:
$ 1.76万 - 项目类别:
ER and post-ER quality control of integral membrane proteins
完整膜蛋白的 ER 和 ER 后质量控制
- 批准号:
10428489 - 财政年份:2019
- 资助金额:
$ 1.76万 - 项目类别:
Modulating Hsp70-dependent proteostasis in Alzheimer's Disease
调节阿尔茨海默病中 Hsp70 依赖性蛋白质稳态
- 批准号:
10118403 - 财政年份:2019
- 资助金额:
$ 1.76万 - 项目类别:
FASEB SRC on Protein Folding in the Cell
FASEB SRC 关于细胞中蛋白质折叠的研究
- 批准号:
8720195 - 财政年份:2014
- 资助金额:
$ 1.76万 - 项目类别:
2009 Stress Proteins in Growth, Development, and Disease Gordon Research Conferen
2009 年生长、发育和疾病中的应激蛋白戈登研究会议
- 批准号:
7663377 - 财政年份:2009
- 资助金额:
$ 1.76万 - 项目类别:
相似海外基金
CAREER: Biochemical and Structural Mechanisms Controlling tRNA-Modifying Metalloenzymes
职业:控制 tRNA 修饰金属酶的生化和结构机制
- 批准号:
2339759 - 财政年份:2024
- 资助金额:
$ 1.76万 - 项目类别:
Continuing Grant
Leveraging releasable aryl diazonium ions to probe biochemical systems
利用可释放的芳基重氮离子探测生化系统
- 批准号:
2320160 - 财政年份:2023
- 资助金额:
$ 1.76万 - 项目类别:
Standard Grant
Diurnal environmental adaptation via circadian transcriptional control based on a biochemical oscillator
基于生化振荡器的昼夜节律转录控制的昼夜环境适应
- 批准号:
23H02481 - 财政年份:2023
- 资助金额:
$ 1.76万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Systematic manipulation of tau protein aggregation: bridging biochemical and pathological properties
tau 蛋白聚集的系统操作:桥接生化和病理特性
- 批准号:
479334 - 财政年份:2023
- 资助金额:
$ 1.76万 - 项目类别:
Operating Grants
Converting cytoskeletal forces into biochemical signals
将细胞骨架力转化为生化信号
- 批准号:
10655891 - 财政年份:2023
- 资助金额:
$ 1.76万 - 项目类别:
Enhanced Biochemical Monitoring for Aortic Aneurysm Disease
加强主动脉瘤疾病的生化监测
- 批准号:
10716621 - 财政年份:2023
- 资助金额:
$ 1.76万 - 项目类别:
Biochemical Mechanisms for Sustained Humoral Immunity
持续体液免疫的生化机制
- 批准号:
10637251 - 财政年份:2023
- 资助金额:
$ 1.76万 - 项目类别:
Structural and biochemical investigations into the mechanism and evolution of soluble guanylate cyclase regulation
可溶性鸟苷酸环化酶调节机制和进化的结构和生化研究
- 批准号:
10604822 - 财政年份:2023
- 资助金额:
$ 1.76万 - 项目类别:
Chemical strategies to investigate biochemical crosstalk in human chromatin
研究人类染色质生化串扰的化学策略
- 批准号:
10621634 - 财政年份:2023
- 资助金额:
$ 1.76万 - 项目类别:
Examination of risk assessment and biochemical assessment of fracture development focusing on the body composition of patients with rheumatoid arthritis
关注类风湿性关节炎患者身体成分的骨折发生风险评估和生化评估检查
- 批准号:
22KJ2600 - 财政年份:2023
- 资助金额:
$ 1.76万 - 项目类别:
Grant-in-Aid for JSPS Fellows














{{item.name}}会员




